艾迪注射液联合同步放化疗治疗食管癌临床观察.docVIP

艾迪注射液联合同步放化疗治疗食管癌临床观察摘 要 目的：观察艾迪注射液联合同步放化疗治疗食管癌的疗效和不良反应。方法：收治食管癌患者62例，随机分为两组，艾迪注射液组(A组)31例采用艾迪注射液联合同步放化疗的方法；对照组(B组)31例采用单纯同步放化疗的方法。艾迪注射液组中艾迪注射液80ml+NS 400ml，d1～d14/周期。治疗期间每周观察骨髓抑制、放射性食管炎、消化道反应等不良反应。同步放化疗结束后2周观察患者机能状态及免疫功能。放化疗后3个月、12个月评价有效率(CR+PR)。结果：艾迪注射液组和对照组总有效率分别为9355%和8710%(P＞005)。对照组不良反应大于艾迪注射液组，骨髓抑制、胃肠道反应及放射性食管炎发生率差异有显著性(P＜001)。结论：艾迪注射液联合同步放化疗治疗食管癌能减轻放化疗的不良反应，提高肿瘤患者的生存质量，并能提高有效率。 关键词 艾迪注射液 食管癌 同步放化疗 doi:10.3969/j.issn.1007-614x.2012.14.195 Abstract Objective:to observe the eddy injection joint chemoradiation treatment in patients with cancer of the esophagus efficacy and side effects.Methods:the March 2008～2009 12 menstrual pathology esophageal for 62 cases of patients,randomly divided into two groups:eddy injection group(group A)31 cases by the eddy injection chemoradiation joint the method;The control group(group B)31 cases by the simple method of chemoradiation alone.Eddy injection group eddy injection 80 ml+NS 400ml,d1～d14/cycle.A week during treatment of bone marrow suppression,observe radioactive esophagitis,gastrointestinal reaction and other side effects.Two weeks after the chemoradiation observe patients functional status and immune function.Radiation and chemotherapy after 3 months,12 months evaluation efficient(CR+PR).Results:eddy injection group and control group total effectiveness 93.55% and 87.10%,respectively(P＞005).The control group side effects than eddy injection group， bone marrow,suppression,gastrointestinal reaction and radioactive esophagitis rate(P＜0.01).Conclusion:eddy injection joint chemoradiation treatment can reduce esophageal the adverse reaction of radiation and chemotherapy,improve the quality of life of patients with cancer,and can improve the efficient,deserves further study confirmed. Key Words eddy injection;Esophageal;chemoradiation 本研究应用艾迪注射液联合放化疗治疗食管癌，并与单纯放化疗进行比较，分析其近期疗效及不良反应。现将结果报告如下。 资料与方法 2008年3月～2009年12月收治食管癌患者62例，将患者随机分为两组，每组各31例，艾迪注射液组采用艾迪注射液联合同步放化疗的方法，对照组采用单纯同步放化疗的方法。两组的一般资料无显著性差异(P＞005)。